The company is ramping up its in-house manufacturing capacity to fill injection pens for its diabetes drug Ozempic and for the European version of its hugely popular weight-loss drug Wegovy, a senior executive told Reuters on Thursday.
Capsida Biotherapeutics Inc. and Kate Therapeutics announced a strategic partnership to leverage Capsida’s expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx’s initial internal portfolio of muscle and heart disease programs.
The company plans to expand its manufacturing capacity at the Research Triangle Park facility in North Carolina to support increased demand for its key diabetes drugs. It has been struggling to meet high demand for the drugs Trulicity and Mounjaro, especially due to production of multiple dosage forms for each of them.
The facility, bought from a Novartis unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.
Novartis said on Thursday that it would cut up to 400 jobs in Ireland, or about a quarter of its workforce there, as part of a previously announced restructuring program that will cut 8,000 jobs globally.
Dr. Reddy’s Laboratories Ltd. announced the recognition of the global pharmaceutical company’s largest manufacturing facility in Bachupally, Hyderabad, as part of the Global Lighthouse Network (GLN) by the World Economic Forum (WEF).
Under the expanded deal, AstraZeneca’s will have access to Oxford Biomedica’s Oxbox manufacturing facility to produce its shot on an as-needed basis beyond 2022.
In the absence of global standards limiting toxic emissions produced by antibiotics at the point of manufacture, the pharmaceutical industry has come up with its own standard. The AMR Industry Alliance – a coalition of drugmakers, biotech, diagnostic and other companies involved in the field of antimicrobials – is adopting its own standards to ensure the responsible manufacture of antibiotics.
Astellas Pharma Inc. President and CEO Kenji Yasukawa, Ph.D., today announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C. The facility will allow Astellas Pharma to expand the company’s resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope.
To bolster the increased demand for mRNA therapies, Germany’s Evonik Industries, in partnership with the U.S. government, is investing more than $200 million to build a lipid manufacturing facility in the United States.